TP53 and acute myeloid leukemia: Studies of AML suggest that the TP53 mutation rate remains as low as 10%17–20, while MDM2 is frequently overexpressed21–23, rendering the P53-MDM2 axis an attractive pharmacologic target for small-molecule inhibitors.